Expression of proteolytic enzymes in head and neck cancer-associated fibroblasts.
OBJECTIVE
To elucidate tumor-stromal interactions during tumor invasion by assessing the expression of proteolytic enzymes by carcinoma-associated fibroblasts (CAFs) in vivo using complementary DNA (cDNA) array analysis.


METHODS
Tumor-associated stroma was isolated from tumor and adjacent mucosal specimens of the same patient by laser capture microdissection, and the messenger RNA (mRNA) was assessed by cDNA microarray specific for proteolytic enzymes and their inhibitors. Protein overexpression was then analyzed by immunoblotting of primary fibroblast isolates derived from skin, mucosa, and tumor specimens.


RESULTS
Array analysis of 4 tumor and 4 adjacent mucosal samples demonstrated significant (2.6-fold) overexpression of membrane type 1 matrix metalloproteinase (MT1-MMP) but not of serine proteases or other matrix metalloproteinases. Analysis of normal dermal fibroblasts, normal mucosal fibroblasts, and CAFs similarly demonstrated up-regulation of MT1-MMP.


CONCLUSIONS
These results suggest that MT1-MMP mRNA is specifically up-regulated in CAFs in vivo whereas MT1-MMP protein is specifically up-regulated in CAFs in vitro. Known to induce tumor cell invasion when expressed in tumor cells, CAF expression of MT1-MMP may be important in the stromal response to tumor cells that characterizes the desmoplastic reaction.
Rosenthal
Eben L
EL
Department of Surgery, Division of Otolaryngology--Head and Neck Surgery, University of Alabama at Birmingham, Birmingham, AL 35249, USA. eben.rosenthal@ccc.uab.edu
McCrory
Allison
A
Talbert
Melissa
M
Carroll
William
W
Magnuson
J Scott
JS
Peters
Glenn E
GE
D014408:Biomarkers, Tumor / Q000096:biosynthesis*; D002294:Carcinoma, Squamous Cell / Q000201:enzymology* / Q000378:metabolism*; D002454:Cell Differentiation / Q000502:physiology; D018076:DNA, Complementary / Q000378:metabolism; D004273:DNA, Neoplasm / Q000378:metabolism; D042783:Endothelial Cells / Q000166:cytology / Q000378:metabolism / Q000473:pathology; D005347:Fibroblasts / Q000201:enzymology*; D058851:GPI-Linked Proteins; D006258:Head and Neck Neoplasms / Q000201:enzymology* / Q000378:metabolism*; D006801:Humans; D020782:Matrix Metalloproteinases / Q000378:metabolism; D053504:Matrix Metalloproteinases, Membrane-Associated; D008562:Membrane Glycoproteins / Q000378:metabolism; D008666:Metalloendopeptidases / Q000378:metabolism; D009055:Mouth / Q000166:cytology / Q000378:metabolism / Q000473:pathology; D009061:Mouth Mucosa / Q000166:cytology / Q000378:metabolism / Q000473:pathology; D020411:Oligonucleotide Array Sequence Analysis; D009960:Oropharynx / Q000166:cytology / Q000378:metabolism / Q000473:pathology; D010447:Peptide Hydrolases / Q000096:biosynthesis*; D012334:RNA, Neoplasm / Q000378:metabolism; D012867:Skin / Q000166:cytology / Q000378:metabolism / Q000473:pathology; D019714:Tissue Inhibitor of Metalloproteinases / Q000378:metabolism; D014407:Tumor Cells, Cultured; D015854:Up-Regulation / Q000502:physiology
D014408:Biomarkers, Tumor; D018076:DNA, Complementary; D004273:DNA, Neoplasm; D058851:GPI-Linked Proteins; D008562:Membrane Glycoproteins; C115460:RECK protein, human; D012334:RNA, Neoplasm; D019714:Tissue Inhibitor of Metalloproteinases; D010447:Peptide Hydrolases; D020782:Matrix Metalloproteinases; D053504:Matrix Metalloproteinases, Membrane-Associated; D008666:Metalloendopeptidases